a 2017

B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia

KOČKOVÁ, Helena, Karla PLEVOVÁ, Jitka MALČÍKOVÁ, Jana KOTAŠKOVÁ, Vojtěch BYSTRÝ et. al.

Basic information

Original name

B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia

Authors

KOČKOVÁ, Helena (203 Czech Republic, belonging to the institution), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Vojtěch BYSTRÝ (203 Czech Republic, belonging to the institution), Veronika MANČÍKOVÁ (703 Slovakia, belonging to the institution), Martin TRBUŠEK (203 Czech Republic, belonging to the institution), Michaela HLOŽKOVÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution)

Edition

CEITEC PHD RETREAT II, 2017

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

10606 Microbiology

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14740/17:00096943

Organization unit

Central European Institute of Technology

Keywords in English

CLL; receptor; genomic defects

Tags

Změněno: 17/5/2018 13:58, Mgr. Pavla Foltynová, Ph.D.

Abstract

V originále

B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia, B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia

Links

LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1106/2016, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)
Investor: Masaryk University, Category A
NV15-31834A, research and development project
Name: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie